Beneficial Effect of Quercetin on Erythrocyte Properties in Type 2 Diabetic Rats - PubMed (original) (raw)
Beneficial Effect of Quercetin on Erythrocyte Properties in Type 2 Diabetic Rats
Tomas Jasenovec et al. Molecules. 2021.
Abstract
Diabetes mellitus is characterized by tissue oxidative damage and impaired microcirculation, as well as worsened erythrocyte properties. Measurements of erythrocyte deformability together with determination of nitric oxide (NO) production and osmotic resistance were used for the characterization of erythrocyte functionality in lean (control) and obese Zucker diabetic fatty (ZDF) rats of two age categories. Obese ZDF rats correspond to prediabetic (younger) and diabetic (older) animals. As antioxidants were suggested to protect erythrocytes, we also investigated the potential effect of quercetin (20 mg/kg/day for 6 weeks). Erythrocyte deformability was determined by the filtration method and NO production using DAF-2DA fluorescence. For erythrocyte osmotic resistance, we used hemolytic assay. Erythrocyte deformability and NO production deteriorated during aging-both were lower in older ZDF rats than in younger ones. Three-way ANOVA indicates improved erythrocyte deformability after quercetin treatment in older obese ZDF rats only, as it was not modified or deteriorated in both (lean and obese) younger and older lean animals. NO production by erythrocytes increased post treatment in all experimental groups. Our study indicates the potential benefit of quercetin treatment on erythrocyte properties in condition of diabetes mellitus. In addition, our results suggest potential age-dependency of quercetin effects in diabetes that deserve additional research.
Keywords: ZDF; Zucker diabetic fatty rats; age; diabetes mellitus; erythrocyte; erythrocyte deformability; nitric oxide; quercetin.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Figure 1
Basic characteristics of experimental animals: body weight/tibia ratio (A), body weight gain (B), blood glucose concentration (C), systolic blood pressure (D). Abbreviations: C—lean control vehicle-treated, CQ—lean control quercetin-treated, D—Zucker diabetic fatty (ZDF) vehicle-treated, DQ—ZDF quercetin-treated. * p < 0.05 versus 6-month-old C group, + p < 0.05 versus 6-month-old D group, # p < 0.05 versus age-matched C group, $ p < 0.05 versus age-matched D group. Data are presented as means ± standard deviations.
Figure 2
Parameters of lipid metabolism. Concentration of total cholesterol (A), triglycerides (B), HDL-cholesterol (C), LDL-cholesterol (D). Abbreviations: C—lean control vehicle-treated, CQ—lean control quercetin-treated, D—Zucker diabetic fatty (ZDF) vehicle-treated, DQ—ZDF quercetin-treated. * p < 0.05 versus 6-month-old C group, + p < 0.05 versus 6-month-old D group, # p < 0.05 versus age-matched C group. Data are presented as means ± standard deviations.
Figure 3
Parameters of oxidative stress and antioxidant status determined by ferric reducing antioxidant power (FRAP) in blood plasma: thiobarbituric acid reactive substances (TBARS) (A), advanced oxidation protein products (AOPP) (B), fructosamine (C), FRAP (D). Abbreviations: C—lean control vehicle-treated, CQ—lean control quercetin-treated, D—Zucker diabetic fatty (ZDF) vehicle-treated, DQ—ZDF quercetin-treated. * p < 0.05 versus 6-month-old C group, + p < 0.05 versus 6-month-old D group, # p < 0.05 versus age-matched C group, $ p < 0.05 versus age-matched D group. Data are presented as means ± standard deviations.
Figure 4
Parameters of erythrocytes: erythrocyte deformability (A), nitric oxide production by erythrocytes (B), osmotic resistance of erythrocytes determined by the concentration of NaCl providing 50% hemolysis—IC50 (C). Abbreviations: C—lean control vehicle-treated, CQ—lean control quercetin-treated, D—Zucker diabetic fatty (ZDF) vehicle-treated, DQ—ZDF quercetin-treated. * p < 0.05 versus 6-month-old C group, + p < 0.05 versus 6-month-old D group, # p < 0.05 versus age-matched C group. Data are presented as means ± standard deviations.
Similar articles
- Quercetin Ameliorates Testicular Damage in Zucker Diabetic Fatty Rats through Its Antioxidant, Anti-Inflammatory and Anti-Apoptotic Properties.
Tvrdá E, Kováč J, Ferenczyová K, Kaločayová B, Ďuračka M, Benko F, Almášiová V, Barteková M. Tvrdá E, et al. Int J Mol Sci. 2022 Dec 16;23(24):16056. doi: 10.3390/ijms232416056. Int J Mol Sci. 2022. PMID: 36555696 Free PMC article. - Asymmetric dimethylarginine reduced erythrocyte deformability in streptozotocin-induced diabetic rats.
Yang ZC, Xia K, Wang L, Jia SJ, Li D, Zhang Z, Deng S, Zhang XH, Deng HW, Li YJ. Yang ZC, et al. Microvasc Res. 2007 Mar;73(2):131-6. doi: 10.1016/j.mvr.2006.04.008. Epub 2006 Nov 13. Microvasc Res. 2007. PMID: 17098259 - Differences in plasma homocysteine levels between Zucker fatty and Zucker diabetic fatty rats following 3 weeks oral administration of organic vanadium compounds.
Wasan KM, Risovic V, Yuen VG, McNeill JH. Wasan KM, et al. J Trace Elem Med Biol. 2006;19(4):251-8. doi: 10.1016/j.jtemb.2005.10.001. Epub 2005 Dec 13. J Trace Elem Med Biol. 2006. PMID: 16443173 - Matrix Metalloproteinases and Their Role in Mechanisms Underlying Effects of Quercetin on Heart Function in Aged Zucker Diabetic Fatty Rats.
Boťanská B, Barteková M, Ferenczyová K, Fogarassyová M, Kindernay L, Barančík M. Boťanská B, et al. Int J Mol Sci. 2021 Apr 24;22(9):4457. doi: 10.3390/ijms22094457. Int J Mol Sci. 2021. PMID: 33923282 Free PMC article. - Activation of angiotensin type 2 (AT2) receptors prevents myocardial hypertrophy in Zucker diabetic fatty rats.
Castoldi G, di Gioia CRT, Roma F, Carletti R, Manzoni G, Stella A, Zerbini G, Perseghin G. Castoldi G, et al. Acta Diabetol. 2019 Jan;56(1):97-104. doi: 10.1007/s00592-018-1220-1. Epub 2018 Sep 5. Acta Diabetol. 2019. PMID: 30187136
Cited by
- Alterations in Antioxidant Status and Erythrocyte Properties in Children with Autism Spectrum Disorder.
Jasenovec T, Radosinska D, Jansakova K, Kopcikova M, Tomova A, Snurikova D, Vrbjar N, Radosinska J. Jasenovec T, et al. Antioxidants (Basel). 2023 Nov 28;12(12):2054. doi: 10.3390/antiox12122054. Antioxidants (Basel). 2023. PMID: 38136174 Free PMC article. - Aging in Normotensive and Spontaneously Hypertensive Rats: Focus on Erythrocyte Properties.
Radosinska J, Kollarova M, Jasenovec T, Radosinska D, Vrbjar N, Balis P, Puzserova A. Radosinska J, et al. Biology (Basel). 2023 Jul 21;12(7):1030. doi: 10.3390/biology12071030. Biology (Basel). 2023. PMID: 37508459 Free PMC article. - Alterations in Oxidative Stress Markers and Na,K-ATPase Enzyme Properties in Kidney after Fructose Intake and Quercetin Intervention in Rats.
Vrbjar N, Vlkovicova J, Snurikova D, Kalocayova B, Zorad S, Culafic T, Tepavcevic S, Tothova L, Radosinska D, Kollarova M, Radosinska J. Vrbjar N, et al. Life (Basel). 2023 Apr 2;13(4):931. doi: 10.3390/life13040931. Life (Basel). 2023. PMID: 37109460 Free PMC article. - Quercetin alleviates diastolic dysfunction and suppresses adverse pro-hypertrophic signaling in diabetic rats.
Bartosova L, Horvath C, Galis P, Ferenczyova K, Kalocayova B, Szobi A, Duris-Adameova A, Bartekova M, Rajtik T. Bartosova L, et al. Front Endocrinol (Lausanne). 2022 Dec 8;13:1029750. doi: 10.3389/fendo.2022.1029750. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36568083 Free PMC article. - Quercetin Ameliorates Testicular Damage in Zucker Diabetic Fatty Rats through Its Antioxidant, Anti-Inflammatory and Anti-Apoptotic Properties.
Tvrdá E, Kováč J, Ferenczyová K, Kaločayová B, Ďuračka M, Benko F, Almášiová V, Barteková M. Tvrdá E, et al. Int J Mol Sci. 2022 Dec 16;23(24):16056. doi: 10.3390/ijms232416056. Int J Mol Sci. 2022. PMID: 36555696 Free PMC article.
References
- Zhou Z., Mahdi A., Tratsiakovich Y., Zahorán S., Kövamees O., Nordin F., Gonzalez A.E.U., Alvarsson M., Östenson C.-G., Andersson D.C., et al. Erythrocytes From Patients With Type 2 Diabetes Induce Endothelial Dysfunction Via Arginase I. J. Am. Coll. Cardiol. 2018;72:769–780. doi: 10.1016/j.jacc.2018.05.052. - DOI - PubMed
- Shin S., Ku Y.H., Ho J.X., Kim Y.K., Suh J.S., Singh M. Progressive impairment of erythrocyte deformability as indicator of microangiopathy in type 2 diabetes mellitus. Clin. Hemorheol. Microcirc. 2007;36:253–261. - PubMed
MeSH terms
Substances
Grants and funding
- APVV-18-0287/Agentúra na Podporu Výskumu a Vývoja
- VEGA 1/0193/21/Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
- VEGA 2/0153/21/Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
- VEGA 2/0104/20/Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous